Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives $20.40 Average PT from Brokerages

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $20.40.

A number of research analysts recently issued reports on TLX shares. Royal Bank Of Canada cut shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Wednesday, September 2nd. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Finally, Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. XY Capital Ltd lifted its stake in shares of Telix Pharmaceuticals by 468.0% in the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after acquiring an additional 58,739 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new stake in Telix Pharmaceuticals during the 2nd quarter valued at approximately $1,731,000. Bank of America Corp DE raised its holdings in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares during the last quarter. Lazard Asset Management LLC raised its holdings in Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares during the last quarter. Finally, Private Advisor Group LLC lifted its position in shares of Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after purchasing an additional 128,070 shares during the period.

Telix Pharmaceuticals Stock Performance

Telix Pharmaceuticals stock opened at $11.94 on Thursday. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. The stock’s fifty day moving average price is $11.22 and its two-hundred day moving average price is $10.02. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $12.48.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.